MAP4K4 and Alzheimer disease: The results showed that compared with HCs, the mRNA expression levels of PDGFRB, PLOD1, MAP4K4, and NFKBIA were significantly elevated in AD patients (Figure 9), suggesting they may have the potential to be diagnostic biomarkers for AD.